Latest News
Wednesday November 5, 2008 — CuraGen Corporation
BRANFORD, Conn., Nov. 5 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Dr. Timothy M. Shannon, President and Chief Executive Officer, will present a corporate update at the Rodman Renshaw Annual Global Investme...
Monday November 3, 2008 — CuraGen Corporation
BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Dr. Patrick Hwu, ...
Monday November 3, 2008 — CuraGen Corporation
BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation , today reported its financial results for the third quarter of 2008.During the three month period ended September 30, 2008, CuraGen utilized $3.6 million of cash for operations and ended the quarter with $91.4 million of cash ...
Wednesday October 29, 2008 — CuraGen Corporation
BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008 following the release of thir...
Friday September 26, 2008 — CuraGen Corporation
BRANFORD, Conn., Sept. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, today announced that it received a letter, dated September 23, 2008, from The NASDAQ Stock Market, notifying CuraGen that during the preceding 30 consecutive t...
Thursday September 11, 2008 — CuraGen Corporation
BRANFORD, Conn., Sept. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, today announced that it has completed the enrollment of patients into its Phase II trial evaluating CR011-vcMMAE for the treatment of advanced melanoma. CuraGe...
Tuesday July 29, 2008 — CuraGen Corporation
BRANFORD, Conn., July 29 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, today reported its financial results for the second quarter of 2008 and updated clinical progress of CR011-vcMMAE.For the quarter ended June 30, 2008, CuraGen r...
Wednesday June 25, 2008 — CuraGen Corporation
BRANFORD, Conn., June 25 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.The Phase II trial is an open-label, multi-center study of C...
Wednesday June 25, 2008 — Zacks.com: Analyst Blog
The proceeds from the sale of Belinostat, for treating solid tumors and hematologic malignancies, strengthened CuraGen Corporation's (CRGN) balance sheet, but further weakened its pipeline, especially after the termination of its key clinical program Velafermin for the treatment of severe...
Wednesday June 11, 2008 — CuraGen Corporation
BRANFORD, Conn., June 11 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma has met the effic...
Monday June 9, 2008 — Fingad.com
Sadbhav Engineering aquire OBCL - by raghni4949 Sadbhav Engineering, a construction firm will acquire 74 per cent stake in Hong Kong based Ocean Bright Corporation Limited (OBCL) for an undisclosed amount. The acquisition was carried out through the wholly owned subsidiary of the company Sadbhav ...
Friday June 6, 2008 — CuraGen Corporation
BRANFORD, Conn., June 6 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that Dr. Timothy Shannon, President and Chief Executive Officer, will present at The Seventh Annual Needham Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008, at 3:30 p.m. Eas...
Monday June 2, 2008 — CuraGen Corporation
BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation today presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma. The results were presented by Dr. Patrick Hwu, Co-Principal Investigator,...
Friday May 30, 2008 — CuraGen Corporation
BRANFORD, Conn., May 29 /PRNewswire-FirstCall/ -- CuraGen Corporation today announced that it had received notification from The NASDAQ Stock Market that the Company has regained compliance with the requirements for continued listing on the NASDAQ Global Market, and that this matter is now close...
Friday May 23, 2008 — CuraGen Corporation
BRANFORD, Conn., May 22 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today the completion of a series of privately negotiated transactions in which the Company sold the 5,000,000 shares of TopoTarget common stock issued to the Company as partial payment for the sale of CuraGen's owner...
Wednesday May 14, 2008 — CuraGen Corporation
BRANFORD, Conn., May 14 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today the completion of a series of privately negotiated transactions with holders of the Company's 4% Convertible Subordinated Notes due February 2011 (the "2011 Notes") in which the Company retired a total of $50.9...
Tuesday April 22, 2008 — CuraGen Corporation
BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- CuraGen Corporation today reported its financial results for the first quarter of 2008. For the quarter ended March 31, 2008, CuraGen reported a net loss of $6.8 million, or $0.12 per share, compared to a net loss of $17.0 million, or $0.31 pe...
Tuesday April 22, 2008 — CuraGen Corporation
BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company, announced today that it has sold its ownership in belinostat, a Phase I/II histone deacetylase inhibitor, to TopoTarget A/S (Copenhagen Stock Exchange: TOPO) for approximately $39...
Friday April 18, 2008 — Zacks.com: Analyst Blog
CuraGen Corporation (CRGN) is a biopharmaceutical company focused on oncology. The sale of 454 Life Sciences to Roche will reduce CuraGen's top-line growth dramatically in the coming years, but will strength its balance sheet and provide resource for advancing its clinical programs.
How...
Wednesday April 9, 2008 — CuraGen Corporation
BRANFORD, Conn., April 9, 2008 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that it has advanced CR011-vcMMAE, an antibody-drug conjugate (ADC), into Phase II for the treatment of patients with unresectable Stage I...
Tuesday February 12, 2008 — CuraGen Corporation
BRANFORD, Conn., Feb. 12 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that Timothy M. Shannon, M.D., President and Chief Executive Officer, will present at the BIO CEO Investor Conference on Wednesday, February 13, 2008, at 3:30 p.m. Eastern Standard Time.Access to a live webca...
Thursday January 31, 2008 — CuraGen Corporation
BRANFORD, Conn., Jan. 31 /PRNewswire-FirstCall/ -- CuraGen Corporation today reported its consolidated financial results for the fourth quarter and fiscal year ended December 31, 2007.CuraGen reported a loss from operations for the fourth quarter of 2007 of $11.0 million, or $0.20 per share, whi...
Wednesday January 30, 2008 — CuraGen Corporation
BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, today announced that it received a letter, dated January 28, 2008, from The NASDAQ Stock Market, notifying CuraGen that during the preceding 30 consecutive trad...
Thursday January 24, 2008 — CuraGen Corporation
BRANFORD, Conn., Jan. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call to discuss CuraGen's fourth quarter and year end 2007 financial results at 11:00 a.m. ...
Tuesday May 1, 2007 — Zacks.com: Analyst Blog
Zacks senior genomics industry analyst Grant Zeng, CFA is maintaining his Buy rating on shares of CuraGen Corporation (CRGN), a genomics-based biotech firm. Here's what he had to say about it in today's Buy report:
CuraGen Corporation is a biopharmaceutical company engaged in devel...